DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 2390--------------------------------------------------
(Abst.) PACTRIMS 2019: Trial of in-home natalizumab infusions
By: agate Date: February 6, 2019, 12:23 am
---------------------------------------------------------
Biogen funded this study, presented at the 2019 PACTRIMS
(Pan-Asian Committee on Treatment and Research in MS)
conference, trying out in-home infusions of natalizumab:
[font=arial]MS Treatment: Other Drugs[/font]
Patients’ Perspectives on a Changed Model of Care from
Out-patients to The Home for the Infusion of Natalizumab
Juaton MS[sup]1[/sup], Cusack L[sup]1[/sup], Schultz
TJ[sup]1[/sup], Thomas A[sup]2[/sup], Georgiou P[sup]3[/sup],
Simon L[sup]3[/sup], Naidoo K[sup]4[/sup], Webb K[sup]5[/sup],
Karnon J[sup]6[/sup], Ravindran J[sup]5[/sup]
[sup]1[/sup]Adelaide Nursing School, University of Adelaide,
Adelaide, Australia 5005; [sup]2[/sup]Post Op Care at Home (Pty
Ltd), McLaren Vale, Australia 5171; [sup]3[/sup]Ambulatory Care
Day Unit, Royal Adelaide Hospital, Adelaide, Australia 5005;
[sup]4[/sup]Biogen Australia and New Zealand, North Ryde,
Australia 2113; [sup]5[/sup]Neurology Department, Royal Adelaide
Hospital, Adelaide, Australia 5005; [sup]6[/sup]School of Public
Health, University of Adelaide, Adelaide, Australia 5005
Conflict of interest: The research was Funded by Biogen
Australia and New Zealand as investigator initiated research. Ms
Anne Thomas is Director of Post-Op Care At Home (Pty Ltd). This
organisation was sub-contracted to deliver the home care
nursing. Ms Kerisha Naidoo is an employee of Biogen.
Background: This paper presents the qualitative component of a
study on the safety and clinical effectiveness, acceptability
and cost effectiveness of home infusions of natalizumab for
people with Multiple Sclerosis (MS). We compared the home
nursing model of care with the usual care (an out-patient
intravenous therapy service) in a randomised cross-over trial
that included a qualitative component.
Objective: The objective was to understand the experiences and
perspectives of people who have received home infusions using
the new model of care.
Methods: This study was conducted using an exploratory
descriptive methodology. Twelve of the 37 participants consented
for a face-to-face interview. The transcripts were thematically
analysed using the Braun and Clark approach.
Results: The outcome from the interviews and analysis revealed
eight subthemes, which were grouped into two main themes; ‘the
experience’ and ‘convenience’. The findings indicated that being
at home while receiving natalizumab infusions offers physical
and emotional comfort for MS patients and their family. The
benefits of delivering this infusion at home included no travel
or car parking costs, no waiting in the hospital and comfort
within the home environment. It was an easy and stress free
experience for most participants. This study found that MS
patients preferred receiving their natalizumab infusions at
home.
Conclusion: Patients’ voices must be used to inform
patient-centred care. Home infusions of natalizumab are a safe
alternative model of care and provide patient benefits such as
flexibility, reduced costs and an improved patient experience.
These findings should inform future healthcare delivery.
*****************************************************